A real-world study of the longitudinal course of itch severity and frequency in adults with atopic dermatitis

Hong, Mindy; Lei, Donald; Yousaf, Muhammad; Chavda, Rajeev; Gabriel, Sylvie; Janmohamed, Sherief R.; Silverberg, Jonathan I.

doi:10.1007/s00403-021-02214-1

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continued improvement at 30–36 months was also observed for measures of AD-related sleep disturbance and HRQoL, where 85% of patients achieved a clinically meaningful improvement in DLQI score and more than half (53%) reported that AD had no effect on their lives. It has been reported that, in patients with AD, the longitudinal course of itch, sleep disturbances, and HRQoL are heterogeneous, with these symptoms manifesting fluctuating patterns over time [ 22 – 24 ]. However, the sustained benefits in these outcomes that were reported by patients over the entire assessment period suggest that the improvements relative to baseline likely result from treatment effects rather than fluctuation in symptom presentation.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Kimball

Delevry

Yang

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients’ perspective. The aim of this study was to evaluate patient-reported outcomes (PROs) during long-term dupilumab treatment. Methods Adults with moderate-to-severe AD who initiated dupilumab through the US manufacturer patient support program and participated in RELIEVE-AD (a prospective patient survey study with a 12-month follow-up) were recontacted 30–36 months post-initiation regardless of current dupilumab use. The online questionnaire consisted of PROs, including the Atopic Dermatitis Control Tool (ADCT), use of concomitant AD therapies, satisfaction with current therapy, global change in itch relative to before dupilumab initiation, non-itch skin symptoms (skin pain/soreness, hot/burning feeling, and sensitivity to touch), flares, Dermatology Life Quality Index, sleep problems, and the AD-specific Work Productivity and Activity Impairment Questionnaire. Results Of 698 patients who initiated dupilumab (baseline) and were recontacted, 425 completed the 30–36-month survey. Significant reductions from baseline were reported in concomitant AD therapy use ( P < 0.05); 54.4% reported not using other AD medications vs. 12.8% at baseline. At 30–36 months, all results (non-itch skin symptoms, flares, sleep problems, health-related quality of life work/activity impairment, disease control, and treatment satisfaction) were similar to or incrementally better than the 12-month timepoint, with significant improvements vs. baseline ( P < 0.001). Global change in itch was reported as “very much better” by 75.3% of respondents. Adequate disease control (score < 7 on ADCT) was reported by 80.7% of respondents, and 86.8% were satisfied with the treatment. Conclusions In clinical practice settings, patient-reported benefits of dupilumab were maintained in survey respondents during long-term treatment up to 36 months while the use of concomitant AD therapies reduced. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-00965-5.

show abstract

Section: Discussionmentioning

confidence: 99%